| Disease | OF THE TRIAL. GINKGO BILOBA EXTRACT ADMINISTRATION APPEARS TO IMPROVE PREEXISTING VISUAL FIELD DAMAGE IN SOME PATIENTS WITH NTG.
8.13+/-2.12 DB (T=9.89, P=0.0001, CHI-SQUARE TEST). NO SIGNIFICANT CHANGES WERE FOUND IN INTRAOCULAR PRESSURE, BLOOD PRESSURE, OR HEART RATE AFTER PLACEBO OR GBE TREATMENT. ANY OCULAR AND SYSTEMIC SIDE EFFECTS WERE RECORDED FOR THE DURATION
DEVIATION (MD) AT BASELINE VERSUS MD AFTER GBE TREATMENT, 11.40+/-3.27 DB VERSUS 8.78+/-2.56 DB (T=8.86; P=0.0001, CHI-SQUARE TEST); CORRECTED PATTERN STANDARD DEVIATION (CPSD) AT BASELINE VERUS CPSD AFTER GBE TREATMENT, 10.93+/-2.12 DB VERSUS
AT BASELINE AND AT THE END OF EACH PHASE OF THE STUDY, WERE EVALUATED FOR CHANGES. CHANGE IN VISUAL FIELD AND ANY OCULAR OR SYSTEMIC COMPLICATIONS. AFTER GBE TREATMENT, A SIGNIFICANT IMPROVEMENT IN VISUAL FIELDS INDICES WAS RECORDED: MEAN
FOLLOWED BY A WASH-OUT PERIOD OF 8 WEEKS, THEN 4 WEEKS OF PLACEBO TREATMENT (IDENTICAL CAPSULES FILLED WITH 40 MG FRUCTOSE). OTHER PATIENTS UNDERWENT THE SAME REGIMEN, BUT TOOK THE PLACEBO FIRST AND THE GBE LAST. VISUAL FIELD TESTS, PERFORMED
PROSPECTIVE, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-MASKED CROSS-OVER TRAIL. TWENTY-SEVEN PATIENTS WITH BILATERAL VISUAL FIELD DAMAGE RESULTING FROM NTG. PATIENTS RECEIVED 40 MG GBE, ADMINISTERED ORALLY, THREE TIMES DAILY FOR 4 WEEKS, |